SEC Comment Letter 0000000000-23-010681 to Sonoma Pharmaceuticals, Inc. (SNOA)
Sonoma Pharmaceuticals, Inc.
Date: Sept. 27, 2023 · CIK: 0001367083 · Accession: 0000000000-23-010681
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-274582
Letter
United States securities and exchange commission logo September 27, 2023 Amy Trombly Chief Executive Officer Sonoma Pharmaceuticals, Inc. 5445 Conestoga Court, Suite 150 Boulder, CO 80301 Re:Sonoma Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed September 19, 2023 File No. 333-274582 Dear Amy Trombly: We have limited our review of your registration statement to those issues we have addressed in our comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments. Registration Statement on Form S-1 filed September 19, 2023 Cover Page 1.Please revise your cover page to disclose the date the offering will end. Refer to Item 501(b)(8)(iii) of Regulation S-K for guidance. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.
FirstName LastNameAmy Trombly Comapany NameSonoma Pharmaceuticals, Inc. September 27, 2023 Page 2 FirstName LastName Amy Trombly Sonoma Pharmaceuticals, Inc. September 27, 2023 Page 2 Please contact Cindy Polynice at 202-551-8707 or Jason Drory at 202-551-8342 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Andrew J. Merken, Esq.
Show Raw Text
United States securities and exchange commission logo
September 27, 2023
Amy Trombly
Chief Executive Officer
Sonoma Pharmaceuticals, Inc.
5445 Conestoga Court, Suite 150
Boulder, CO 80301
Re:Sonoma Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed September 19, 2023
File No. 333-274582
Dear Amy Trombly:
We have limited our review of your registration statement to those issues we have
addressed in our comments. In some of our comments, we may ask you to provide us with
information so we may better understand your disclosure.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe our comments apply to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to these comments, we may have additional comments.
Registration Statement on Form S-1 filed September 19, 2023
Cover Page
1.Please revise your cover page to disclose the date the offering will end. Refer to
Item 501(b)(8)(iii) of Regulation S-K for guidance.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
FirstName LastNameAmy Trombly
Comapany NameSonoma Pharmaceuticals, Inc.
September 27, 2023 Page 2
FirstName LastName
Amy Trombly
Sonoma Pharmaceuticals, Inc.
September 27, 2023
Page 2
Please contact Cindy Polynice at 202-551-8707 or Jason Drory at 202-551-8342 with any
other questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Andrew J. Merken, Esq.